However, the production and clearance of cell-free DNA from plasma in relation to its methylation status, are poorly understood processes.
Introduction
Cell-free human genomic DNA occurs in the plasma of healthy individuals [1] . The DNA molecules are heterogeneous in size, with the majority ranging from 100 bp to 2 kb, and their numbers vary between individuals, 50-2000 diploid genome equivalents/ml blood being typical for a particular DNA sequence. The origins and clearance of the cell-free plasma (cfp) DNA are poorly understood [2] . However, it has been concluded from studies of sex-mismatched bone marrow transplant patients, that most of the cfp DNA originates from the hematopoietic lineage [3] . Proposed mechanisms for the production of cfp DNA include 'accidental' lysis of nucleated blood cells, apoptosis, and a derivation from nuclei ejected from maturing erythrocytes [2] . A significant contribution from vascular endothelial cells has been excluded [4] .
In pathological conditions and pregnancy, cfp DNA can clearly originate elsewhere.
Thus, there has been much effort in analysing DNA markers in patients with solid tumours [5, 6] . In these situations the quantity and methylation status of DNA regions derived from oncogenes or tumour suppressor genes provide biomarkers for disease progression and prognosis [1] . The changes in DNA methylation status indicate changes in gene expression of the relevant biomarker genes; for example, hypermethylated APC gene DNA in plasma may be a useful biomarker of aggressive disease in esophageal adenocarcinoma patients [7] . In pregnancy, a proportion (typically 3-6%) of the cell-free DNA in maternal plasma is of fetal genotype, originating largely from the placenta [8, 9] . Cell-free fetal DNA can be detected from as early as 5 weeks after conception [10] , and provides a basis for fetal chromosomal gender determination (using SRY or DYS14 markers [11] ), and for detection of an RhD+ fetus carried by a RhD-mother [12] . In those examples fetal DNA is distinguished from the maternal 'background' by its paternal genotype. In other,
proposed, applications particular cell-free fetal DNA biomarker sequences in maternal plasma are to be distinguished on the basis of their characteristic methylation status. This is the rationale for minimally-invasive genetic diagnoses of fetal aneuploidies (such as Down's syndrome), using a peripheral blood sample from the mother [13] .
It has been concluded from studies of cell-free fetal DNA in plasma that the DNA is cleared very rapidly, with a half-life of under an hour, after delivery of the fetus [14] .
It remains unknown whether cfp DNA turns over with similar rapidity in healthy nonpregnant adults, although this seems likely. A known potential effect that may influence amounts of methylated and unmethylated cfp DNA in the circulation arises from interactions of DNA with cells of the immune system. Bacterial DNA with unmethylated CpG dinucleotides is immunostimulatory [15] , and hypomethylated DNA from peripheral blood monocytes stimulates an autoimmune response in SLE [16] . The amount of cfp DNA is small (typically 50-2000 ge/ml blood) relative to the numbers of cells of the immune system, of various classes, present in blood. So it is conceivable that clearance of cfp DNA depends in part upon a methylation-dependent interaction with the immune system in healthy adults.
In view of the interest in the methylation of cfp DNA for providing biomarkers, we have investigated whether the methylation of the DNA influences its abundance in the plasma of healthy adults. As a critical test, we have examined the abundance of genomic DNA molecules derived from the imprinted GNAS1 locus, which encodes the alpha subunit of the stimulatory G protein, G s .
Materials and Methods

Plasma and cellular DNA
Peripheral venous blood (10ml) was obtained from individual adult donors, with appropriate ethical approval. Blood was collected into EDTA and centrifuged at 1,600
x g for 10 min, and the plasma fraction was recentrifuged at 16,000 x g for 10 min.
Plasma was stored frozen at -80°C until required. DNA was extracted using a QIAmp Blood Maxi kit (Qiagen, UK) using the 'Purification of DNA from whole blood' spin protocol, according to the manufacturer's instructions. Peripheral blood leukocyte genomic DNA, isolated from buffy coat preparations from individual donors, was purchased from BioChain (Hayward, California USA).
Bisulfite conversion
Genomic leukocyte DNA (10µg) was bisulfite-converted using a protocol described previously [17] . For cell-free plasma DNA the bisulfite protocol was modified to allow for the small quanitity of plasma DNA obtained. The plasma DNA was mixed with carrier DNA (2.5 μg of bacterial plasmid DNA) before bisulfite treatment, which was carried out as above, but at 95°C for 5 minutes followed by 55°C for 3.5 hours.
PCR amplification, cloning and sequencing
To amplify the GNAS1 region for digestion with FnuDII, the following primers were used 5' ctt cca aaa agg gac cca tc 3' and 5' agc ctc ctc tct tcc cac tc 3'. To amplify the GNAS1 region after bisulfite conversion, bisulfite-specific primer pairs (Bsps), were used. The Bsp primers were designed using MethPrimer software [18] .
The primers were 5' gat ttt ttt tgt ttt tat gga ttt agg 3' and 5' cta acc aac taa acc tcc tct ctt c 3'. No CpG dinucleotides are included in Bsp sequences, to allow the amplification of both methylated and unmethylated sequences. PCR amplifications were performed as follows: 95°C for 3 min, (95°C for 30 s, 55°C annealing for 30 s, 72°C for 60 s) for 35 cycles, with a final step at 72°C for 10 min. PCRs were carried out in 25µl, including each Bsp primer at 0.4 µM, 2 units of Platinum Taq DNA polymerase (Invitrogen), and 4.0 µl of bisulfite-treated DNA, and standard PCR components. PCR products were purified using QIAquick PCR Purification Kit (Qiagen, UK), eluted in 50 µl of H 2 O. For DNA sequence analysis, the amplified DNA was cloned into the pGEM-T Easy (Promega) vector.
Results
The GNAS1 locus (Fig. 1 ) on chromosome 20 is imprinted, displaying parent-oforigin-dependent DNA methylation that regulates the complex transcriptional activity of this locus [19] . The region of DNA that comprises the XL promoter, first intron and first exon has been shown to be methylated in the maternal allele, in a number of adult tissues. The paternal allele is unmethylated in this DNA region. This region of differential methylation also includes a common single nucleotide polymorphism, rs1800905, which is an A/G difference [20] .
The SNP provides an opportunity to distinguish between alleles from different parents in heterozygous individuals. This A/G SNP creates a restriction site polymorphism (Fig.1) . for the restriction enzyme FnuDII whose target site is CGCG. This was exploited to detect individuals heterozygous for the SNP, using amplicons of the relevant region obtained by PCR amplification of cfp DNA obtained from a number of individual healthy adult plasma donors.
The ability to detect SNP heterozygotes in this way (data not shown) immediately indicated that both paternal and maternal alleles were represented in cfp DNA.
Making the assumption that parent-of-origin differential methylation is maintained in this adult DNA source, this finding suggested that both methylated and unmethylated molecules were represented in cfp DNA in readily detectable amounts.
To enable us to interrogate the methylation status of several CpG sites in the GNAS1 imprinted region, and to directly examine the representation of methylated and unmethylated DNA molecules in cfp DNA in detail, we employed bisulfite conversion. Treatment of DNA with bisulfite converts unmethylated cytosine residues to uracil residues. Following PCR amplification by a DNA polymerase (such as Taq DNA polymerase) that is tolerant of uracil in DNA, unmethylated cytosine residues appear as thymine in the amplified product. Methylated cytosine residues are resistant to conversion by bisulfite [17] .
Following bisulfite conversion of cfp DNA from SNP heterozygous donors, part of the differentially methylated region was amplified using bisulfite-specific primers. In addition, bisulfite converted cfp DNA from some homozygous donors was similarly processed, as well as leukocyte DNA to represent genomic DNA isolated directly from a cellular source. The region targeted by the bisulfite-specific primers contains four or five CpG dinucleotides, depending upon whether it is derived from the A or G SNP allele respectively (Fig. 1) . For each plasma donor, amplicons were cloned in a plasmid vector, and numbers of independent recombinant plasmids were DNAsequenced. The presence of C residues in the DNA sequences indicated methylated C residues at each of the four or five CpG sites (Fig. 2) .
The results for leukocyte cellular DNA obtained from two heterozygous donors demonstrated clear parent-of-origin-dependent methylation. For the leukocyte cellular DNA from donor 6, the A allele is hypomethylated, with the G allele hypermethylated; and vice versa for donor 7 (Fig. 2) . Although overall the imprinting is distinct between the two alleles, as expected from previous work on methylation of this locus in other tissues there is a certain amount of variation in the methylation status of the two alleles, with a small proportion of methylated CpG sites in the presumed paternal allele and unmethylated sites in the presumed maternal allele.
Combining data from both individuals, 19 maternal and 16 paternal alleles were recovered, which is consistent with the expectation that there is no bias in our experimental system for the bisulfite conversion, PCR, cloning and sequencing of the two alleles, i.e. that both alleles are recovered equally.
For the plasma DNA from three individual heterozygous donors, 1-3, the results also showed distinct imprinting, with clear parent-of-origin-dependent methylation. In each case the A allele was the hypomethylated allele, presumed to be paternal.
Combining data for all three heterozygotes, 27 maternal and 24 paternal alleles were recovered, consistent with the hypothesis that there is equal representation of both alleles in cfp DNA. For such data, it could be argued that dividing the data into maternal (hypermethylated) and paternal (hypomethylated) classes on the basis of the SNP ignores partially-methylated molecules, where presence of even a single methylated CpG site might be significant in determining abundance in cfp DNA.
However, the variations from complete hyper-or hypomethylation in cfpDNA are similar to those seen in the cellular DNA, indicating that the population of molecules in cfp DNA does in fact reflect cellular DNA. 
Discussion
Analysing an imprinted locus in the cell-free component of blood has provided, for the first time, a critical test for the steady-state concentrations of methylated and unmethylated cfp DNA. This test has the advantage that it is focused on a single DNA sequence (or two allelic sequences that differ only by an SNP) and is therefore independent of assumptions about equal representations of completely unrelated sequences in plasma.
We have found that the population of cfp DNA contains equal numbers of both maternal and paternal alleles, with their characteristic different methylation profiles, which correspond with the methylation profiles found in cellular DNA sources. We can therefore conclude that methylation has no effect upon the representation of the GNAS1 DNA molecules in plasma. We suggest that this is likely to be generally true for cfp DNA from other genomic regions, with the possible exception of heterochromatinised regions of the genome, such as the inactive X-chromosome in females, or Alu repeat sequences which are highly methylated, associated with a closed chromatin configuration, and present in increased proportions in serum when compared to unique gene sequences [21] . Such methylated regions may persist as nucleosomes in the circulation, perhaps protecting the DNA from degradation [22] .
Although the production and clearance of cfp DNA from the circuation are not well understood processes [2] , it is likely that our finding of equal representation in the steady state can be seen as indicating equal rates of clearance of the two allelic forms from the circulation. Our data indicate that interaction with cells of the immune system [23] , and other potential factors affecting clearance, do not in fact lead to differential clearance of methylated and unmethylated DNA from the circulation in healthy adults. A consequence of this conclusion is that the quantity of a specific methylated (or unmethylated) cell-free DNA biomarker in plasma is a reliable indication of the release of the biomarker by a tumour for cancer studies, or by the placenta for minimally-invasive prenatal diagnosis of fetal aneuploidy. 
